Sub-Saharan Africa is home to a billion people and to overlapping health burdens, including the world’s highest rates of both malaria and HIV infection.
(left to right) The Galega officinalis (aka French lilac)was used as a folk remedy for diabetes symptoms for centuries before analysis of its extracts revealed compounds that lowered blood sugar. Eventually, metformin (molecule and pill) was developed. It is a related molecule that is longer acting and less toxic than the plant extracts. Metformin acts on cells in the liver (center and cross-section right) to reduce glucose production and thus blood sugar.
In people with type 2 diabetes, the body is less able to use the hormone insulin to regulate blood sugar. The disease affects 350 million patients globally—including 29 million in the United States, where it is the leading cause of blindness, kidney failure, and non-accident-related amputations.
Images of P. aeruginosa biofilm—a bacterial community that takes the form of mushroom-like structures. Main/upper left image looks down at the biofilm, the lower/righthand images show cross-sections. This biofilm was cultured from the airways of a patient with cystic fibrosis.
Nearly every human bacterial infection—including some of the most serious, life threatening, and costly to treat—can take the form of a biofilm, in which bacteria aggregate into structured communities that enclose themselves within a secreted slime.
Spiked rods of uric acid crystals from synovial fluid photographed under a microscope with polarized light. In patients with gout, such crystals can accumulate in the joints, causing pain and inflammation.
Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.
I am a theoretical systems pharmacologist who develops advanced simulation methods to improve multiscale mechanistic explanations of complex phenomena in the presence and absence of therapeutic interventions.
My research focuses on pharmacodynamic optimization for the treatment of multi-drug resistant organisms such as Pseudomonas aeruginosa. I am particularly interested in dosing strategies to combat biofilm-mediated infections such as cystic fibrosis.
I am a Professor of Clinical Pharmacy and a Board Certified in Psychiatric Pharmacy (BCPP) with a strong interest in the pharmacological management of mood disorders, particularly in perinatal populations. I have additional expertise in the field of pharmacokinetics, particularly as it applies to potential drug interactions, and conducting epidemiological research relating to psychotropic medications. I am committed to optimizing the medical management of the mentally ill and remain actively involved with various professional organizations and the community at large to achieve this goal.
